Aduro BioTech, Inc. announces an oral presentation, entitled “Modified STING-Activating Cyclic Dinucleotide Derivatives Significantly Enhance the Anti-Tumor Activity of Therapeutic Vaccines,” at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting in National Harbor, Maryland. Thomas W. Dubensky, Jr., chief scientific officer of Aduro, will be presenting at 10:45 am on Saturday, November 9, 2013.
Help employers find you! Check out all the jobs and post your resume.
